Warner Pharmaceuticals announced that the company recently received the “Drug Registration Certificate” for metazolidine bitartrate injections approved and issued by the State Drug Administration. This drug is suitable for preventing various conditions such as acute hypotension in the spinal canal during anesthesia. Methydroxylamine bitartrate injections obtained drug registration certificates according to the newly registered classification of 3 types of chemicals, which is deemed to have passed the consistency evaluation. The acquisition of this drug registration certificate has further enriched the variety of the company's pharmaceutical products and is of positive significance in optimizing the company's product structure.

Warner Pharmaceuticals announced that the company recently received the “Drug Registration Certificate” for metazolidine bitartrate injections approved and issued by the State Drug Administration. This drug is suitable for preventing various conditions such as acute hypotension in the spinal canal during anesthesia. Methydroxylamine bitartrate injections obtained drug registration certificates according to the newly registered classification of 3 types of chemicals, which is deemed to have passed the consistency evaluation. The acquisition of this drug registration certificate has further enriched the variety of the company's pharmaceutical products and is of positive significance in optimizing the company's product structure.